Detalhe da pesquisa
1.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Ann Hepatol
; 15(3): 333-49, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27049487
2.
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
Gastroenterology
; 135(2): 459-67, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18585385
3.
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Pharmacoeconomics
; 21(5): 341-9, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12627987
4.
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Am J Gastroenterol
; 101(11): 2523-9, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17029610
5.
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
J Hepatol
; 39(1): 106-11, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12821051